Alexion Announces Restructuring to Advance Corporate Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Alexion Pharmaceuticals (ALXN) PT Raised to $158 at Deutsche Bank Following Restructuring News
September 13, 2017 7:54 AM EDTDeutsche Bank raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158.00 (from $153.00) while maintaining a Buy rating following the company's restructuring announcement.
Analyst... More
Alexion Pharmaceuticals (ALXN) PT Raised to $182 at Leerink Partners
September 13, 2017 6:46 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $182.00 (from $170.00) while maintaining a Outperform rating following yesterday's reconstructing news.
Analyst Geoffrey Porges sees more good news to come, gMG Plus leverage offers upside.
... MoreAlexion Pharmaceuticals (ALXN) PT Raised to $180 at SunTrust Robinson Humphrey
September 12, 2017 1:38 PM EDTSunTrust Robinson Humphrey analyst Yatin Suneja raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $180.00 (from $170.00) while maintaining a Buy rating after the company announced a restructuring to re-align the company with its previously announced strategic plan.
Suneja commented, "While today's... More
Alexion Pharmaceuticals (ALXN) PT Raised to $173 at BMO Capital
September 12, 2017 11:59 AM EDTBMO Capital analyst M. Ian Somaiya raised his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $173.00 (from $168.00) while maintaining a Outperform rating as the company's plan to cut 20% of its workforce leading to $250mn annual savings was foreshadowed by prior guidance of non-GAAP operating... More
